All In Biotech

Drug Trial Radar · NCT06197009

Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis

A Randomized, Double-blinded, Phase II, Placebo-controlled Study to Evaluate the Safety and Efficacy of SCT650C in Participants With Axial Spondyloarthritis

Last checked: Nov 19, 2026Latest source record: Jan 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

168

Planned (sponsor's estimate)

Start

Jul 1, 2024

Primary completion

Jul 1, 2026

Study completion Aug 1, 2026

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Jan 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SCT650C in patients with Axial Spondyloarthritis

Conditions

  • Axial Spondyloarthritis

Interventions

  • SCT650CDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Axial Spondyloarthritis Reporting Adverse Events (AEs), Serious Adverse Events (SAEs), and Treatment Emergent Adverse Events (TEAEs)Time frame: 48 Weeks
  2. Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) ResponseTime frame: week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hacettepe University Faculty of Medicine

    Ankara, Hacettepe Mh., Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.